| abstract |
The present invention relates to an immunosuppressive reversion oligonucleotide comprising 12 to 18 nucleotides, wherein at least one of the nucleotides is modified, and the oligonucleotide is a sequence of SEQ ID NO: 1 (human) and / or SEQ ID NO: 2 (mouse) Reference is made to oligonucleotides that hybridize with the nucleic acid sequence of the extracellular enzyme of (CD73) and inhibit at least 50% of CD73 expression. The present invention is further directed to pharmaceutical compositions comprising such oligonucleotides. |